MultiCell has focused its technologies on four disease targets: multiple sclerosis (MS); type-1 diabetes; and infectious disease. The Company’s therapeutic pipeline includes MCT-125, directed at treating chronic fatigue in MS patients; MCT-175, targeting relapse-remitting MS; MCT-275, for the treatment of type-1 diabetes; and MCT-465, addressing influenza A infection. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery and for the production of therapeutic proteins.